Serendipity Biopharma (LQDA) files Form 144 for $4.23M sale

Rhea-AI Filing Summary

Serendipity Biopharma LLC files a Form 144 reporting proposed sales of 100,000 shares of common stock. The notice lists an aggregate intended sale price of $4,228,000.00 and an intended sale date of 05/08/2026. The excerpt shows multiple executed 10b5-1 sales from 04/09/2026 through 05/07/2026, including several 25,000-share transactions under a 10b5-1 plan.

Insights

Securities Compliance Analyst

Notice describes routine, planned insider dispositions under a 10b5-1 arrangement.

The filing reports a proposed aggregate sale of $4,228,000.00 for 100,000 shares with multiple executed 10b5-1 sales dated between 04/09/2026 and 05/07/2026. The pattern and explicit "10b5-1 Sales" labels indicate pre-arranged plan executions rather than ad hoc open-market trades.

Cash-flow treatment and ultimate purchaser identities are not listed in the excerpt; subsequent SEC filings or broker reports would show settlement details and final disposition timing.

Market Liquidity Specialist

Series of 10b5-1 sales could create steady sell-side supply across the listed dates.

The excerpt lists multiple sales sizes, frequently 25,000 shares, and one 32,744-share sale by Roger Jeffs; aggregate proceeds shown total $4,228,000.00. These staggered transactions suggest execution in tranches rather than a single block trade.

Impact on trading liquidity depends on average daily volume for the ticker; the excerpt does not provide volume context, so market impact cannot be assessed here.

Key Figures

Proposed sale amount: 100,000 shares Aggregate intended sale price: $4,228,000.00 Individual 10b5-1 sale (05/07/2026): 25,000 shares +3 more

6 metrics

Proposed sale amount 100,000 shares Form 144 cover fields

Aggregate intended sale price $4,228,000.00 Form 144 cover fields

Individual 10b5-1 sale (05/07/2026) 25,000 shares Proceeds $1,052,135.00

Individual 10b5-1 sale (05/06/2026) 25,000 shares Proceeds $1,019,572.50

Roger Jeffs sale (04/13/2026) 32,744 shares Proceeds $1,256,387.28

Earlier single trade (04/14/2026) 3,300 shares Proceeds $132,000.00

Key Terms

Form 144, 10b5-1 Sales, Aggregate intended sale price, Proposed sale amount

4 terms

Form 144 regulatory

"Form 144 reporting proposed sale of 100,000 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

10b5-1 Sales regulatory

"Multiple transactions labeled as 10b5-1 Sales from 04/09/2026 to 05/07/2026"

Aggregate intended sale price financial

"Aggregate intended sale price of $4,228,000.00 shown on cover"

Proposed sale amount financial

"Proposed sale amount listed as 100,000 shares in the cover fields"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	4228000.00	88114429	05/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			100000	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	05/07/2026	25000	1052135.00
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	05/06/2026	25000	1019572.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	05/05/2026	25000	1002592.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/17/2026	18839	764955.71
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/16/2026	25000	1007800.00
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/15/2026	25000	1003522.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/14/2026	3300	132000.00
ROGER JEFFS 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/13/2026	32744	1256387.28
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/10/2026	21433	859876.96
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/09/2026	25000	1002887.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Serendipity Biopharma's Form 144 report for LQDA?

The Form 144 reports a proposed sale of 100,000 shares of common stock for an aggregate price of $4,228,000.00. It also lists multiple executed 10b5-1 sales dated between 04/09/2026 and 05/07/2026.

Were the trades reported executed under a 10b5-1 plan for LQDA?

Yes. The excerpt repeatedly labels transactions as 10b5-1 Sales, indicating they were made pursuant to a pre-arranged trading plan. Dates shown include 04/09/2026 through 05/07/2026.

How many shares and what aggregate proceeds are shown in the Form 144?

The filing shows an intended sale of 100,000 shares with an aggregate intended sale price of $4,228,000.00. Individual executed trade proceeds are listed per trade in the excerpt.

Who is listed as selling or executing some transactions in the excerpt?

The excerpt shows sales by Serendipity Biopharma LLC and a named seller, Roger Jeffs, with a 32,744-share sale recorded on 04/13/2026. Other trades are labeled as 10b5-1 sales by the LLC.

Do the reported transactions indicate cash proceeds to the issuer?

No. The Form 144 lists sales by selling holders; proceeds are shown as aggregate values per trade, but the excerpt does not state the issuer receives proceeds. The sales appear to be holder dispositions.